pepmg_

Study summary · research use only

Delta sleep-inducing-peptide-like immunoreactivity (DSIP-LI) and delta sleep in schizophrenic volunteers

Study · human · Sleep · 1992 · DOI 10.1093/sleep/15.6.519 · PMID 1475566

Plain-language summary

Paraphrased from the published abstract below — not a verdict on whether anything works.

In this human study, the authors measured cerebrospinal fluid delta sleep-inducing-peptide-like immunoreactivity (DSIP-LI) in 15 drug-free male subjects diagnosed with schizophrenia, who underwent lumbar puncture and three nights of polysomnography. They report that CSF DSIP-LI was significantly correlated with polysomnography from the prior night, positively with stage 3 sleep (p = 0.05), with stage 3 and delta sleep in the first NREM period, and with a NREM-period ratio, and negatively with stage 2% sleep. The authors describe this as a first report of a possible relationship between CSF DSIP-LI and slow-wave sleep in humans and note that generalization awaits further study.

Abstract

Delta sleep-inducing-peptide (DSIP) has been reported to increase sleep in subjects with insomnia. The authors studied cerebrospinal fluid (CSF) DSIP-like immunoreactivity (DSIP-LI) in 15 drug-free male subjects with a DSM-IIIR diagnosis of schizophrenia. The subjects underwent a lumbar puncture and three nights of polysomnography. CSF DSIP-LI was significantly correlated with polysomnography the night before the LP: with stage 3 sleep (p = 0.05), stage 3 and delta (stages 3 + 4) sleep during the first nonrapid eye movement NREM period (p = 0.02 and p = 0.05, respectively) and the ratio of the first and second NREM period (p < 0.05), and negatively with stage 2% sleep (p < 0.05). Whether this first report of a potential relationship between CSF DSIP-LI and slow-wave sleep in man might be generalized to sleep in nonpsychiatric subjects awaits further study.

Read the full study on PubMed ↗

pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.